Menthol should not be given a free pass based on studies of biomarkers of toxicity

Pamela I Clark1, Phillip Gardiner

  • 1Department of Behavioral and Community Health, School of Public Health, University of Maryland College Park, MD 20742, USA. clarkp@umd.edu

Insights

Menthol cigarettes may pose broader public health risks beyond direct toxicity. Current harm assessments are too narrow, failing to capture the full impact of menthol in tobacco products.

Area of Science:

  • Tobacco regulatory science
  • Public health research
  • Toxicology

Background:

  • Menthol cigarettes are widely used, particularly among youth and minority populations.
  • Studies comparing menthol and nonmenthol cigarette toxicity have yielded inconsistent findings.
  • Cigarette manufacturers often cite these mixed results to claim no added harm from menthol.

Purpose of the Study:

  • To critically evaluate the definition of harm used in assessing menthol cigarettes.
  • To advocate for a broader public health perspective on menthol's impact.
  • To challenge the tobacco industry's narrow interpretation of harm data.

Main Methods:

  • Review and analysis of existing exposure and toxicity studies on mentholated and non-mentholated cigarettes.
  • Conceptual framework development for assessing broader public health impacts.
  • Critique of industry-sponsored research and its conclusions.

Main Results:

  • Existing studies present mixed results regarding direct toxicity.
  • A narrow focus on direct toxicity overlooks significant public health concerns.
  • The definition of harm requires expansion to encompass menthol's wider effects.

Conclusions:

  • The current definition of harm from menthol cigarettes is inadequate.
  • Menthol cigarettes present broader public health challenges beyond direct toxicity.
  • A comprehensive public health strategy is needed to address menthol's impact.

Related Concept Videos

Toxicity Testing in Animals01:23

Toxicity Testing in Animals

Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
Drug Toxicity: Dose-Dependent Reactions01:24

Drug Toxicity: Dose-Dependent Reactions

Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
Toxicokinetics: Overview01:21

Toxicokinetics: Overview

Studies that assess how a drug is absorbed, distributed, metabolized, and excreted (ADME) at toxic doses are termed toxicokinetics. Understanding toxicokinetics helps predict adverse drug reactions (ADRs) and manage toxicity in humans.Toxicokinetics differs from pharmacokinetics mainly in the dose levels studied, with toxicokinetics focusing on higher toxic doses. The kinetics at these levels can be non-linear due to altered physiological processes. Toxicodynamics examines the relationship...